Thus, MSA does not kill or inactivate immune cells at the doses required for anti-cancer treatment, but rather has an immunostimulatory effect, enhancing the T-cell-mediated destruction of tumor cells by inhibiting tumor-secreted PDL1 and VEGF [89]. Here, VEGFA is linked to neoplasm.